Filing Details
Compass Therapeutics, Inc. (NASDAQ:CMPX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 09, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:CMPX
Compass Therapeutics, Inc. (CMPX) Files Quarterly Report for Q0
Compass Therapeutics, Inc. (NASDAQ:CMPX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 09, 2026.
At publication ·
What changed
Compass Therapeutics, Inc. (NASDAQ:CMPX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Compass Therapeutics filed a quarterly 10-Q report with the SEC on November 09, 2026.
- The company's stock trades at $0.76 per share with a market capitalization of $745.4 million.
- The 10-Q contains unaudited financial statements and management commentary on business performance and emerging risks.
Market Context
Compass Therapeutics, Inc.'s stock currently trades at $0.76 with a market capitalization of $745.4M.
The 10-Q provides Compass Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Compass Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CMPX Stock Page
Frequently Asked Questions
Where can I read CMPX's SEC filings?
Browse all filings on our CMPX SEC filings page.
What types of SEC filings does Compass Therapeutics, Inc. file?
Public companies like Compass Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.